H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Biophytis (BPTS – Research Report) today and set a price target of $15.00. The company’s shares opened today at $0.64.
Pantginis covers the Healthcare sector, focusing on stocks such as Actinium Pharmaceuticals, PDS Biotechnology, and Palatin Technologies. According to TipRanks, Pantginis has an average return of -17.2% and a 29.38% success rate on recommended stocks.
Currently, the analyst consensus on Biophytis is a Moderate Buy with an average price target of $15.00.
See Insiders’ Hot Stocks on TipRanks >>
BPTS market cap is currently $11.38M and has a P/E ratio of -0.19.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Biophytis SA is a France-based biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases.
Read More on BPTS:
